Maravai LifeSciences Holdings, Inc. (MRVI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 284 | 799 | 883 | 289 | 259 | 186 | 209 | 212 |
| Operating profit | $m | -7 | - | ||||||
| Net profit | $m | 77 | 182 | 220 | -119 | -145 | -131 | -77 | -17 |
| EPS reported | $ | -0.91 | -0.54 | ||||||
| Operating cashflow per share | $ | -0.40 | -0.17 | ||||||
| Capex per share | $ | 0.09 | 0.07 | ||||||
| FCF per share | $ | -0.49 | -0.24 | ||||||
| Free cash flow | $m | -71 | -35 | ||||||
| Net debt | $m | -181 | 77 | ||||||
| Book value equity | $m | 212 | 205 | ||||||
| Book value per share | $ | 1.46 | 1.38 | ||||||
| Number of shares | m | 145.07 | 148 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.23 | 4.39 | ||||||
| P/S LTM | x | 4.83 | 4.30 | ||||||
| P/FCF LTM | x | -12.69 | -25.57 | ||||||
| EV/EBITDA LTM | x | -4.87 | -12.52 | ||||||
| EV/Sales LTM | x | 3.86 | 8.05 | ||||||
| Earnings Yield LTM | % | -27.74% | -9.17% | ||||||
| FCF Yield | % | -7.88% | -3.91% | ||||||
| Quality | |||||||||
| ROE | % | -61.58% | -35.42% | ||||||
| ROIC | % | -0.91% | +16.91% | ||||||
| Operating margin | % | -3.63% | +46.02% | ||||||
| Gross margin | % | +17.98% | +34.61% | ||||||
| FCF/Sales | % | -38.08% | -16.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -28.34% | -19.45% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.99 | -0.20 | ||||||
| Net Debt/EBITDA | x | 1.23 | -1.86 | ||||||
| EBIT/Net interest | x | -0.25 | 4.01 | ||||||
| Net debt/market cap | % | +3.96% | +4.91% | ||||||
| Net debt/Equity | x | -0.85 | 0.38 | ||||||
| Gross debt/equity | x | 0.17 | 0.86 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Maravai LifeSciences Holdings, Inc. (MRVI)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free